Heparin-Induced Thrombocytopenia: References

Article Type

Article

Changed

Tue, 12/13/2016 - 12:08

Display Headline

Heparin-Induced Thrombocytopenia: References

Author(s)

Angelique B. Allemand, DNP, RN, ACNP-C, CNS

Bridget Miller Guidry, DNP, FNP-C, CCRN

This is the reference list for the series, "Heparin-Induced Thrombocytopenia." The remaining articles are Introduction; Presentation and History; Diagnosis; and Treatment/Management.

References
1. Kanaan AO, Al-Homsi AS. Heparin-induced thrombocytopenia: pathophysiology, diagnosis, and review of pharmacotherapy. J Pharm Pract. 2009;22:149-157.

2. LaMuraglia GM, Houbballah R, Laposata M. The identification and management of heparin-induced thrombocytopenia in the vascular patient. J Vasc Surg. 2012;55:562-570.

3. Rauova L, Zhai L, Kowalska MA, et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood. 2006;107:2346-2353.

4. Suvarna S, Espinasse B, Qi R, et al. Determinants of PF4/heparin immunogenicity. Blood. 2007;110:4253-4260.

5. Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e495S-e530S.

6. Demma LJ, Winkler AM, Levy JH. A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients. Anesth Analg. 2011;113:697-702.

7. Demma LJ, Levy JH. Diagnosing heparin-induced thrombocytopenia in cardiac surgical patients: not as easy as you think. Anesth Analg. 2011;112:747-749.

8. Alaraj A, Wallace A, Tesoro E, et al. Heparin-induced thrombocytopenia: diagnosis and management. J Neurointervent Surg. 2010;2:371-378.

9. Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355:809-817.

10. Sud S, Mittmann N, Cook DJ, et al. Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation. Am J Resp Crit Care Med. 2011;184:1289-1298.

11. Shaikh N. Heparin-induced thrombocytopenia. J Emerg Trauma Shock. 2011;14:97-102.

12. Cuker A. Heparin-induced thrombocytopenia: present and future. J Thromb Thrombolysis. 2011;31:353-366.

13. Locke CSF, Dooley J, Gerber J. Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs low molecular weight heparin in non-surgical patients are low and similar. Thromb J. 2005;3:4.

14. Cuker A. Recent advances in heparin-induced thrombocytopenia. Curr Opin Hematol. 2011;18:315-322.

15. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest. 2008;133(6 suppl):340S-380S.

16. Junqueira DR, Perini E, Penholati RR, Carvalho MG. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev. 2012;9:CD007557.

17. Berry C, Tcherniantchouk O, Ley EJ, et al. Overdiagnosis of heparin-induced thrombocytopenia in surgical ICU patients. J Am Coll Surg. 2011;213:10-17.

18. Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. Semin Thromb Hemost. 2012;38:31-37.

19. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest. 2005;127(2 suppl):35S-45S.

20. Fennessy-Cooney M. Heparin-induced thrombocytopenia. Nurse Pract. 2011;36:31-37.

21. Bryant A, Low J, Austin S, Joseph JE. Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T's score and particle gel immunoassay. Br J Haematol. 2008;143:721-726.

22. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:759-765.

23. Wirth SM, Macaulay TE, Armistead JA, et al. Evaluation of a clinical scoring scale to direct early appropriate therapy in heparin-induced thrombocytopenia. J Oncol Pharm Pract. 2010;16:161-166.

24. Yoon JH, Jang IK. Heparin-induced thrombocytopenia in cardiovascular patients: pathophysiology, diagnosis, and treatment. Cardiol Rev. 2011;19:143-153.

25. Bartholomew JR. Heparin-induced thrombocytopenia: 2008 update. Curr Treat Options Cardiovasc Med. 2008;10:117-127.

26. Warkentin TE. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med. 2002;126:1415-1423.

27. Badger NO. Fondaparinux (Arixtra^®), a safe alternative for the treatment of patients with heparin-induced thrombocytopenia? J Pharm Pract. 2010;23:235-238.

28. Petros S. Lepirudin in the management of patients with heparin-induced thrombocytopenia. Biologics. 2008;2:481-490.

29. Warkentin TE. How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program. 2011;2011:143-149.

30. Papadopoulos S, Flynn JD, Lewis DA. Fondaparinux as a treatment option for heparin-induced thrombocytopenia. Pharmacotherapy. 2007; 27:921-926.

This is the reference list for the series, "Heparin-Induced Thrombocytopenia." The remaining articles are Introduction; Presentation and History; Diagnosis; and Treatment/Management.

Author and Disclosure Information

Angelique B. Allemand, DNP, RN, ACNP-C, CNS, Bridget Miller Guidry, DNP, FNP-C, CCRN

Issue

Clinician Reviews - 23(5)

Publications

Clinician Reviews

Federal Practitioner

Topics

Cardiology

Page Number

37

Legacy Keywords

Heparin-induced thrombocytopenia, HIT, thrombocytopenia, platelets, platelet factor 4, PF4, antiheparin, anticoagulant, anticoagulation, cardiovascular surgery, American College of Chest Physicians, ACCP, guidelines, unfractionated heparin, UFH, low-molecular-weight heparin, LMWH, postsurgical, thrombosis, deep vein thrombosis, DVT, pulmonary embolism, arterial thrombosis, gangrenous skin lesions, thromboprophylaxis, platelet activation, skin necrosis, platelet count monitoring, HIT antibody testing, immunologic assays, func-tional assays, serotonin release assay, SRA, 4Ts, heparin exposure, non-heparin anticoagulant, direct throm-bin inhibitor, DTI, lepirudin, argatroban, bivalirudin, fondaparinux, warfarin, international normalized ratio, INRHeparin-induced thrombocytopenia, HIT, thrombocytopenia, platelets, platelet factor 4, PF4, antiheparin, anticoagulant, anticoagulation, cardiovascular surgery, American College of Chest Physicians, ACCP, guidelines, unfractionated heparin, UFH, low-molecular-weight heparin, LMWH, postsurgical, thrombosis, deep vein thrombosis, DVT, pulmonary embolism, arterial thrombosis, gangrenous skin lesions, thromboprophylaxis, platelet activation, skin necrosis, platelet count monitoring, HIT antibody testing, immunologic assays, func-tional assays, serotonin release assay, SRA, 4Ts, heparin exposure, non-heparin anticoagulant, direct throm-bin inhibitor, DTI, lepirudin, argatroban, bivalirudin, fondaparinux, warfarin, international normalized ratio, INR

Sections

Clinical Review